
Skyhawk Therapeutics have received the regulatory approval needed to broaden its FALCON-HD trial to include the United States, Canada, and the UK. The expanded trial will enroll up to 400 more people with Stage 2 and early Stage 3 HD across more than 40 sites worldwide.
















